Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer.
作者： Xiaohong Pan , Xiaoli Zhang
关键词:
摘要: Aim: Clinical management of colorectal cancer is challenging. Circulating tumor cells (CTCs) and DNA (ctDNA) are investigated to detect key KRAS mutation for prognosis risk stratifications. Materials & methods: 200 advance-stage patients with metastatic disease were selected followed-up. Serial blood draws used quantify CTCs ctDNA. Results: Both ctDNA strongly associated patients. The positive predictive values 96.5 96.3% among ctDNA, respectively, all using mutation. Specificity healthy controls was 100%. As a indicator, results demonstrated that who had plasma worse outcomes. Conclusion: Blood-based assessment shows promising in early-risk
scilit.net参考文章(29)
Ana Giménez-Capitán, Niki Karachaliou, Miquel Tarón, Jordi Bertran-Alamillo, Rafael Rosell, Santiago Viteri, Maria José Serrano, Carlota Costa, Amaya Gascó, Clara Mayo, Francisco G. Ortega, José Antonio Lorente, Miguel A. Molina-Vila, CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors Translational lung cancer research. ,vol. 2, pp. 65- 71 ,(2013) , 10.3978/J.ISSN.2218-6751.2013.02.06
Heidi Schwarzenbach, Dave S. B. Hoon, Klaus Pantel, Cell-free nucleic acids as biomarkers in cancer patients Nature Reviews Cancer. ,vol. 11, pp. 426- 437 ,(2011) , 10.1038/NRC3066
Ronald Lebofsky, Charles Decraene, Virginie Bernard, Maud Kamal, Anthony Blin, Quentin Leroy, Thomas Rio Frio, Gaëlle Pierron, Céline Callens, Ivan Bieche, Adrien Saliou, Jordan Madic, Etienne Rouleau, François-Clément Bidard, Olivier Lantz, Marc-Henri Stern, Christophe Le Tourneau, Jean-Yves Pierga, Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types Molecular Oncology. ,vol. 9, pp. 783- 790 ,(2015) , 10.1016/J.MOLONC.2014.12.003
Philippe L. Bedard, Aaron R. Hansen, Mark J. Ratain, Lillian L. Siu, Tumour heterogeneity in the clinic Nature. ,vol. 501, pp. 355- 364 ,(2013) , 10.1038/NATURE12627
Florent Mouliere, Bruno Robert, Erika Arnau Peyrotte, Maguy Del Rio, Marc Ychou, Franck Molina, Celine Gongora, Alain R. Thierry, High Fragmentation Characterizes Tumour-Derived Circulating DNA PLoS ONE. ,vol. 6, pp. e23418- ,(2011) , 10.1371/JOURNAL.PONE.0023418
Malcolm S Wilson, Catharine ML West, GD Wilson, Stephen A Roberts, Roger D James, Philip F Schofield, Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. British Journal of Cancer. ,vol. 68, pp. 501- 506 ,(1993) , 10.1038/BJC.1993.376
Fatima Haggar, Robin Boushey, Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors Clinics in Colon and Rectal Surgery. ,vol. 22, pp. 191- 197 ,(2009) , 10.1055/S-0029-1242458
Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran, Daphne W. Bell, Daniel Irimia, Lindsey Ulkus, Matthew R. Smith, Eunice L. Kwak, Subba Digumarthy, Alona Muzikansky, Paula Ryan, Ulysses J. Balis, Ronald G. Tompkins, Daniel A. Haber, Mehmet Toner, Isolation of rare circulating tumour cells in cancer patients by microchip technology Nature. ,vol. 450, pp. 1235- 1239 ,(2007) , 10.1038/NATURE06385
Sandra Misale, Rona Yaeger, Sebastijan Hobor, Elisa Scala, Manickam Janakiraman, David Liska, Emanuele Valtorta, Roberta Schiavo, Michela Buscarino, Giulia Siravegna, Katia Bencardino, Andrea Cercek, Chin-Tung Chen, Silvio Veronese, Carlo Zanon, Andrea Sartore-Bianchi, Marcello Gambacorta, Margherita Gallicchio, Efsevia Vakiani, Valentina Boscaro, Enzo Medico, Martin Weiser, Salvatore Siena, Federica Di Nicolantonio, David Solit, Alberto Bardelli, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature. ,vol. 486, pp. 532- 536 ,(2012) , 10.1038/NATURE11156
Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A Yap, Gerthardt Attard, Udai Banerji, Michelle D Garrett, George V Thomas, Paul Workman, Stan B Kaye, Johann S de Bono, Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discovery Today. ,vol. 15, pp. 88- 97 ,(2010) , 10.1016/J.DRUDIS.2009.11.006